Table 3. Summary of adverse effects.

	Group A (n=30), tenofovir+glycyrrhizin	Group B (n=30), tenofovir	P value
Hypertension (grade 2/3)a	16 (53%)	14 (47%)	0.797
Grade 2	13 (43%)	10 (33%)	0.596
Grade 3	3 (10%)	4 (13%)	1.000
Hypokalemia (<3.5 mmol/l)	15 (50%)	6 (20%)	0.029
3–3.5 mmol/l	12 (40%)	4 (13.3%)	0.039
<3 mmol/l	3 (10%)	2 (6.7%)	1.000
Ascites/leg edema	2 (6.7)	3 (10)	1.000

^aCTCAE 4.03.